Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer

Abstract excerpt

Non-small cell lung cancer (NSCLC) harboring activating EGFR mutations were initially treated by first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), unfortunately, the efficacy of these drugs is limited, mostly frequent due to T790M mutation. Although osimertinib has been approved to treat patients with T790M-positive NSCLC, the majority of patients will develop C797S mutation and suffer diseases again....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Berberine and alkaloids research
• Share to Cancer therapeutics and mechanisms
• Share to Lung Cancer Treatments and Mutations